The Belgian Diabetes in Pregnancy Study (BEDIP-N), a multi-centric prospective cohort study on screening for diabetes in pregnancy and gestational diabetes: methodology and design by Katrien Benhalima et al.
Benhalima et al. BMC Pregnancy and Childbirth 2014, 14:226
http://www.biomedcentral.com/1471-2393/14/226STUDY PROTOCOL Open AccessThe Belgian Diabetes in Pregnancy Study (BEDIP-N),
a multi-centric prospective cohort study on
screening for diabetes in pregnancy and
gestational diabetes: methodology and design
Katrien Benhalima1*, Paul Van Crombrugge2,3, Johan Verhaeghe1, Sofie Vandeginste2, Hilde Verlaenen3,
Chris Vercammen4, Els Dufraimont4, Christophe De Block5, Yves Jacquemyn5, Farah Mekahli6, Katrien De Clippel6,
Roland Devlieger1 and Chantal Mathieu1Abstract
Background: The International Association of Diabetes and Pregnancy Study Groups (IADPSG) recommends
universal screening with a 75 g oral glucose tolerance test (OGTT) using stricter criteria for gestational diabetes
(GDM). This may lead to important increases in the prevalence of GDM and associated costs, whereas the gain in
health is unclear. The goal of ‘The Belgian Diabetes in Pregnancy Study’ (BEDIP-N) is to evaluate the best screening
strategy for pregestational diabetes in early pregnancy and GDM in an ethnically diverse western European
population. The IADPSG screening strategy will be followed, but in addition risk questionnaires and a 50 g glucose
challenge test (GCT) will be performed, in order to define the most practical and most cost effective screening
strategy in this population.
Methods: BEDIP-N is a prospective observational cohort study in 6 centers in Belgium. The aim is to enroll 2563
pregnant women in the first trimester with a singleton pregnancy, aged 18–45 years, without known diabetes
and without history of bariatric surgery. Women are universally screened for overt diabetes and GDM in the first
trimester with a fasting plasma glucose and for GDM between 24–28 weeks using the 50 g GCT and independently
of the result of the GCT, all women will receive a 75 g OGTT using the IADPSG criteria. Diabetes and GDM will be
treated according to a standardized routine care protocol. Women with GDM, will be reevaluated three months
postpartum with a 75 g OGTT. At each visit blood samples are collected, anthropometric measurements are
obtained and self-administered questionnaires are completed. Recruitment began in April 2014.
Discussion: This is the first large, prospective cohort study rigorously assessing the prevalence of diabetes in early
pregnancy and comparing the impact of different screening strategies with the IADPSG criteria on the detection of
GDM later in pregnancy.
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Gestational diabetes (GDM) is a frequent medical condi-
tion during pregnancy and was historically defined as
‘any degree of glucose intolerance with onset or first
recognition during pregnancy’ [1]. GDM has long been
known to raise the risk of a large for gestational age
(LGA) baby and macrosomia resulting in increased rates
of shoulder dystocia and caesarian deliveries [2,3].
Shortly after the delivery the glucose values are gener-
ally restored to normal, but women with GDM have a
seven-fold increased risk of developing type 2 diabetes
(T2DM) [4]. The initial criteria for diagnosis of GDM
were established more than 40 years [5]. These criteria
were chosen to identify women at high risk for devel-
opment of diabetes after pregnancy and not necessarily
to identify pregnancies with increased risk for adverse
perinatal outcome [6].
Meanwhile, two large randomized intervention trials
have demonstrated improvement in perinatal outcomes
in the group of women who received treatment of mild
glucose intolerance during pregnancy, especially in the
frequency of LGA [7,8]. Lack of international uniformity
in the approach to ascertainment and diagnosis of GDM
has been a major hurdle to compare the results of both
studies. The ACHOIS study used a 75 g oral glucose tol-
erance test (OGTT) using the former WHO criteria for
GDM while the study of Landon et al. used a 3-hour
OGTT with the Carpenter & Coustan criteria for GDM
[7,8]. Progressively more data have shown that the risk
of adverse perinatal outcomes is also associated with de-
grees of hyperglycaemia less severe than overt diabetes
during pregnancy. The ‘Hyperglycemia and Adverse Preg-
nancy Outcome Study’ (HAPO), showed a continuous and
graded relationship between maternal hyperglycaemia and
the risk for an adverse perinatal outcome, independent of
other risk factors [2].
In June 2008, the ‘The International Association of
Diabetes and Pregnancy Study Groups’ (IADPSG) orga-
nized a conference leading to a new consensus statement
for a new screening strategy and diagnosis of GDM [9].
Women with overt diabetes are at an increased risk for
congenital anomalies and diabetes complications due to
their greater degree of hyperglycaemia earlier in preg-
nancy [10]. The IADPSG advises therefore to screen for
existing but unknown diabetes at the first prenatal clinic
visit, especially in high risk populations. Cut-offs for
tests used to detect diabetes in the non-pregnant popu-
lation are recommended in early pregnancy [fasting
plasma glucose ≥ 126 mg/dl (7.0 mmol/l), random plasma
glucose ≥ 200 mg/dl (11.1 mmol/l) or HbA1c ≥ 6.5%
(47 mmol/mol)]. If overt diabetes or GDM has not been
diagnosed in early pregnancy or enrollment is at 24 weeks
gestation or later, IADPSG advises that every woman
should undergo a 75 g OGTT. The cut-off values for theFPG, 1-h and 2-h OGTT were chosen to reflect an in-
crease in risk of 75% for the development of a birth
weight > 90th percentile, an umbilical cord C-peptide in
the baby > 90th percentile and percentage body fat in
the baby > 90th percentile. One abnormal value is now
enough to diagnose GDM [FPG ≥ 92 mg/dl (5.1 mmol/l);
1-h plasma glucose ≥ 180 mg/dl (10 mmol/l); 2-h plasma
glucose ≥ 153 mg/dl (8.5 mmol/l)]. By these new criteria,
the total incidence of GDM in the HAPO cohort was
16.1% but with a substantial variation among sites, ranging
from 8.7% in Israel and 23.7% in the US [11]. It is generally
considered that there is not enough evidence to recom-
mend screening and treatment of GDM before 24–28
weeks of gestation. IADPSG recommends now that a
FPG ≥ 92 mg/dl (5.1 mmol/l) in early pregnancy be classi-
fied as GDM [9]. This was mainly reached by consensus
only and uses the cut-off derived from the HAPO study in
the second part of pregnancy.
Internationally, the IADPSG recommendation for
screening for GDM remains controversial since this
will lead to an important increase in the prevalence
of GDM, workload and associated costs. For instance, in
a Norwegian population with 40% from ethnic minorities,
GDM prevalence would increase from 13.0% with the
former WHO criteria to 31.5% with the IADPSG criteria
[12]. Other raised comments are the paucity of data on
the cost effectiveness of such screening strategy, the un-
certainty on the clinical relevance of treatment of mild
GDM based on the IADPSG criteria and the uncertainty
on the risk of women who have had mild GDM to de-
velop T2DM postpartum [13-15]. If the IADPSG would
have chosen the new criteria to be based on an odds
ratio of 2.0 instead of 1.75 for the development of com-
plications in the HAPO study, the threshold for abnor-
mal values would have been higher [FPG ≥ 95 mg/dl
(5.3 mmol/l); 1-h plasma glucose ≥ 191 mg/dl (10.6 mmol/l);
2-h plasma glucose ≥ 162 mg/dl (9.0 mmol/l)] leading
to a much lower GDM prevalence in the HAPO study of
8.8% compared to 16.1% with the current IADPSG criteria
[9]. Another problem is that an OGTT is a poorly reprodu-
cible test [16]. The diagnosis of GDM on the basis of one
abnormal value and based on only 1 test, is consequently a
point of discussion since when repeating the OGTT in the
same women, the test could be completely normal.
So far, two studies have addressed the cost-effectiveness
of GDM screening according to the IADPSG criteria using
decision analysis models for a US population. One study
showed that the IADPSG recommendations are cost effect-
ive only when post-delivery care reduces diabetes incidence
[17]. In the second study management based on the
IADPSG criteria would be effective if treatment would re-
sult in a decreased incidence of preeclampsia with more
than 0.55% and in a decreased incidence of caesarean deliv-
eries of more than 2.7% [18].
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IADPSG recommendations, the American College of
Obstetricians and Gynecologists (ACOG) and an inde-
pendent expert panel assigned by the National Institute
of Health (NIH) continue to promote to use of the two-
step screening strategy, using an universal screening
strategy with the non-fasting 50 g glucose challenge test
(GCT) and if abnormal followed by the 3-hour 100 g
OGTT using the Carpenter & Coustan criteria or the
National Diabetes and Data Group criteria [19,20] [Table 1].
The panel assigned by the NIH was particularly con-
cerned that the adoption of the IADPSG criteria would
increase the prevalence of GDM, and the corresponding
costs without clear demonstration of improvements
in the most clinically important health and patient-
centered outcomes. Recently both the WHO and the
Endocrine Society revised their guidelines and advise
now to implement the IADPSG screening strategy for
GDM [21,22]. The latest 2014 ADA recommendations,
specify that further research is needed to establish a
uniform approach to diagnosing GDM and leave now
open the option between the one-step IADPSG recom-
mendation or the two-step screening strategy as recom-
mended by the NIH Consensus Conference [23]. Table 2
gives an overview of the different international recommen-
dations for screening for GDM.
The need for more research
Data from large prospective cohort studies using the
IADPSG criteria in European populations are currently
lacking. Moreover, there are no cost effective analysis
data based on prospective studies in European popula-
tions comparing the IADPSG screening strategy with the
two-step screening strategy. There are also no accurate
data on the prevalence of GDM in Belgium and the
current practice for screening for GDM varies across
different centers [24]. The lack of consensus on screen-
ing for GDM is also apparent in Belgium. A recent
Flemish consensus between endocrinologists, gynecolo-
gists and general physicians advises at this moment to
continue with the two-step screening strategy while the
recent consensus of the French-speaking obstetriciansTable 1 An overview of the different diagnostic criteria for G
NDDG 3-hour 100 g OGTT
Fasting ≥105 (5.8)
1 h ≥190 (10.6)
2 h ≥165 (9.2)
3 h ≥145 (8.0)
The number of abnormal values needed
for the diagnosis of GDM
≥ 2
Values are presented in mg/dl (mmol/l). NDDG: National Diabetes Data Group; OGT
and Pregnancy Study Groups.is to adopt the proposed IADPSG screening strategy for
GDM [25,26].
Data on the impact of implementing the IADPSG cri-
teria are currently based on retrospective analysis com-
paring the two-step screening strategy or the former
WHO criteria with the IADPSG criteria. These studies
generally show that women former classified normal and
now GDM by the IADPSG criteria, have an impaired
gestational outcome compared to the normal glucose
tolerant (NGT) women [27,28]. We have previously
shown that women prior classified normal by Carpenter
and Coustan criteria and now GDM by the IADPSG cri-
teria have increased rates of caesarean section and shoul-
der dystocia compared to the NGT group [29]. However,
retrospective analyses comparing the former ADA screen-
ing strategy using a 100 g 3 h-OGTT with the IADPSG
criteria have important limitations since comparisons were
drawn on different sets of criteria (the 1-hour and 2-hour
tests could therefore be higher than if a 75-g OGTT would
have been used) and women identified by the IADPSG cri-
teria as GDM but considered NGT using the Carpenter &
Coustan were not treated. Moreover, women were not
universally screened in early pregnancy to exclude an un-
known overt diabetes. Retrospective analysis from our re-
search group has also shown that 36.1% of GDM based on
the IADPSG criteria, had a FPG meeting the threshold for
GDM [30]. In contrast, using the IADPSG screening strat-
egy in a large cohort of the United Arab Emirates, FPG in-
dependently could have avoided the OGTT in 50.6% of
women [31]. This highlights the need to obtain data on
GDM prevalence and data on the glucose measures that
fulfill the diagnostic criteria with the IADPSG criteria in
different populations as this will impact the strategy used
for diagnosis of GDM.
Objective and aims of the Belgian Diabetes in Pregnancy
Study (BEDIP-N)
Since many uncertainties remain concerning the on-step
IADPSG screening strategy for GDM, a large pro-
spective multi-centric cohort study was designed. The
overall objective of the Belgian Diabetes in Pregnancy
Study (BEDIP-N) is to evaluate the impact of the IADPSGDM
Carpenter & Coustan 3-hour 100 g OGTT IADPSG 2-hour 75 g OGTT
≥95 (5.3) ≥92 (5.1)
≥180 (10.0) ≥180 (10.0)
≥155 (8.6) ≥153 (8.5)
≥140 (7.8)
≥ 2 ≥ 1
T: oral glucose tolerance test; IADPSG: The International Association of Diabetes
Table 2 Overview of the different international recommendations for screening for GDM
WHO ➢ IADPSG criteria for GDM
Endocrine Society ➢ One-step screening strategy with IADPSG criteria
ADA Option between:
➢ One-step screening strategy with IADPSG criteria
Or
➢ Two-step screening strategy with 50 g GCT and 100 g OGTT with the Carpenter & Coustan criteria or the NDDG criteria
NIH ➢ Two-step screening strategy with 50 g GCT and 100 g OGTT with the Carpenter & Coustan criteria or the NDDG criteria
ACOG ➢ Two-step screening strategy with 50 g GCT and 100 g OGTT with the Carpenter & Coustan criteria or the NDDG criteria
WHO: World Health Organization; ADA: American Diabetes Association; NIH: National Institute of Health; ACOG: American College of Obstetricians and Gynecologists;
IADPSG: The International Association of Diabetes and Pregnancy Study Groups; GCT: glucose challenge test; OGTT: oral glucose tolerance test; NDDG: National Diabetes
Data Group.
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nancy outcomes in an ethnic diverse population.
Specific aims are:
➢ Aim 1: To evaluate the use of a GCT as an universal
screening tool in a two-step approach with the use
of the 75 g 2-hour OGTT with the IADPSG criteria
only if the GCT is abnormal.
➢ Aim 2: By using a multivariable risk estimation
model based on the most relevant clinical risk
factors and biochemical measures for GDM, the
aim is to develop a simple screening algorithm.
➢ Aim 3: To evaluate differences in GDM prevalence
and pregnancy outcomes using different diagnostic
criteria based on the 75 g OGTT: the IADPSG
criteria, the Carpenter & Coustan criteria and
threshold values if diagnostic criteria would be
based on an odds ratio of 2.0.
➢ Aim 4: To explore the cost effectiveness of the
one-step IADPSG screening strategy.
Methods and Design
Study design and setting
The BEDIP-N is a national multi-centric observational
and prospective cohort study with the participation of 6
centers. The University hospital of Leuven (UZ Leuven)
is the coordination center.
Women are universally screened for overt diabetes and
GDM during the first trimester (recruitment <14 weeks
but first screening test can be delayed until max. 16 weeks)
by measuring the FPG. GDM in early pregnancy is defined
as a FPG ≥100 and ≤125 mg/dl (≥5.5 and ≤6.9 mmol/l), in
line with the definition of prediabetes outside pregnancy
[23]. Overt diabetes in early pregnancy is defined as dia-
betes outside pregnancy [FPG ≥126 mg/dl (7.0 mmol/l)]
[23]. The IADPSG recommendation that a FPG ≥ 92 mg/dl
(5.1 mmol/l) in early pregnancy be classified as GDM
was not adopted since more data are necessary on its
validity. Using a higher FPG cut-off for GDM in early
pregnancy will allow to evaluate the number of womenwith a FPG < 100 mg/dl (5.5 mmol/l) in early pregnancy
to later develop GDM based on the 75 g OGTT with
the IADPSG criteria.
Women without diabetes or GDM in early pregnancy,
will be universally screened for GDM between 24–28
weeks of pregnancy, using the 50 g GCT and independ-
ently of the result of the GCT, will all receive the 75 g
OGTT. The diagnosis of GDM will be based on the 75 g
OGTT with the IADPSG criteria. Participants and re-
searchers will therefore be blinded for the result of the
GCT. The result of the GCT test will later be used to
evaluate the use of a GCT in a two-step approach with
the use of the 75 g OGTT with the IADPSG criteria only
if the GCT is abnormal. Women with GDM, will be ree-
valuated three months postpartum with a 75 g OGTT
using non-pregnancy diagnostic criteria. Women with
diabetes or GDM will be treated according to a stan-
dardized protocol in line with current routine clinical
practice.
Data are collected during early and late pregnancy and
at delivery and for women with GDM also at three
months postpartum. At each visit blood samples are col-
lected, anthropometric measurements are obtained and
self-administered questionnaires are completed. Figure 1
gives an overview of the different steps of the study.
The Belgian National Lottery provides funding for this
investigator-initiated study. The study is registered in
ClinicalTrials.gov as NCT02036619. The study protocol
was approved by the Institutional Review Boards of all
participating centers (Belgian number: B322201420693).
Study sample
Study cohort
The cohort is recruited from 6 centers: UZ Leuven, the
University hospital of Antwerp (UZA), Imelda hospital
Bonheiden, OLV hospital Aalst-site Aalst, OLV hospital
Aalst-site Asse and St Jan hospital Brussels. Five centers
are situated in the Northern part of Belgium: 2 centers
in the province of Flemish-Brabant, 1 center in East-
Flanders and 2 centers in Antwerp. One center is situated
Figure 1 The different steps of the BEDIP-N study.
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between centers with an average number of women from
an ethnic minority background (BME) and centers with a
high percentage of women from a BME background (St
Jan Hospital Brussels and OLV hospital Aalst-site Asse).
UZ Leuven and St Jan Hospital Brussels have a mean num-
ber of deliveries of 2200 per year and the other centers
have between 700–1000 deliveries per year.
The aim is to enroll 2563 pregnant women in the first
trimester over a 2 year recruitment period (see next
paragraph for power calculation). The minimum recruit-
ment planned per center is around 175 women per year
(depending on the center between 100–300 women per
year) with a max. of 25% of the pregnant population that
has to be recruited. Recruitment began in April 2014
and will end around October 2016.The expected duration of the study depends on the re-
sults of the screening tests during pregnancy. If a diagnosis
is made of overt diabetes in early pregnancy or if no GDM
is diagnosed early or later in pregnancy, the study will end
when women and the baby leave the hospital after the de-
livery. For these women, the max. duration of the study
will be 8 months. If women are diagnosed with GDM
(early or later in pregnancy), an extra visit is planned three
months after the delivery. For these women the expected
duration of the trial will be max. 11 months.
Eligibility criteria
The inclusion criteria are:
 women 18–45 years
 a singleton pregnancy
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 viable pregnancy
 delivery planned in the hospital where the study is
performed
The exclusion criteria are:
 < 18 years or > 45 year
 multiple pregnancy
 known diabetes or treatment with metformin
 non-viable pregnancy (miscarriage)
 chronic medical condition (uncontrolled
hypertension, severe heart disease, severe chronic
liver disease, severe chronic kidney disease, chronic
infections such as HIV and hepatitis)
 bariatric surgery
 gastro-intestinal surgery changing the absorption of
glucose (e.g. Billroth II)
 a normal follow up and treatment during pregnancy
will not be possible (incompliance, psychiatric
problems…)
 participating in another study 90 days before the
start of the study
 planned home delivery or in a center not
participating in the study
Power calculation and statistical analyses
We aim at demonstrating a higher proportion of macro-
somia (birth weight >4 Kg) in women with GDM com-
pared to women without GDM based on the IADPSG
criteria. We assume that 5% of recruited women develop
overt diabetes in early pregnancy and will be excluded
from the analysis. We assume that 12.4% of eligible pa-
tients will develop GDM using IADPSG criteria (value
as reported in ATLANTIC-DIP study) [28]. The preva-
lences of macrosomia for GDM and non-GDM cases
used in the calculations are also based on results re-
ported in the ATLANTIC-DIP study [28]. We calculate
that the total number of subjects needed to demonstrate
a difference in proportions of pregnancy complications
with 80% power and 5% significance level, is 2563. The
sample size calculation is based on a two-sided Chi-
square test.
To analyze the overall objective and aim 3 The pro-
portion of GDM cases with 95% confidence intervals will
be estimated for both 2-step and one-step screening
strategies. The difference in proportions between both
screening strategies will be tested using McNemar’s test
for paired proportions. McNemar’s test will be used for
testing differences in proportions between Carpenter &
Coustan criteria and IADPSG criteria, and between
IADPSG criteria and diagnostic criteria based on an
odds ratio of 2.0. All analyses will be performed using allvalid measurements. The chi-square test for proportions
will be used for the comparison of GDM and non-GDM
patients on binary or categorical variables. The Mann–
Whitney U test will be used in case both groups are being
compared on ordinal or continuous variables. A complete
case analysis will be performed including all cases for
which both GDM status and characteristic or complication
are observed.
To analyze aim 1 Sensitivity, specificity, positive pre-
dictive value and negative predictive value will be deter-
mined for the 50 g GCT as a predictor of the result of
the two-step 75 g 2-hour OGTT. The analysis will be
performed using all cases with valid measurements on
both tests.
To analyze aim 2 Logistic regression models will be
used with GDM as binary response variable and pre-
dictor as explanatory variable. Predictor-effects will be
presented as odds ratios with 95% confidence intervals
and p-values will be reported. Besides univariable ana-
lyses, a multivariable prediction model will be built, ul-
timately leading to a risk score definition for predicting
the risk for developing GDM. A backward selection pro-
cedure will be applied for model building. A complete
case analysis is planned, implying that all observations
are used in the analysis for which all model variables are
observed. In case of substantial missing data in predictor
variables leading to power loss in the multivariable ana-
lysis, the technique of multiple imputation for dealing
with missing data will be applied.
To analyze for aim 4 The economic evaluation will es-
tablish the cost-utility of the one-step IADPSG screening
strategy from the health care payer perspective. To cal-
culate QALYs, utility values of relevant health states
(such as perfect health, GDM, preterm birth, permanent
brachial plexus injury) are derived from the literature
and combined with the time spent in the health state.
Clinical data (such as the risk of preterm birth, the risk
of GDM) are derived from the BEDIP-N study. Cost data
are collected by the centers participating in the BEDIP-
N study and are also extracted from the literature. The
cost-utility is calculated as the cost per QALY gained in
the base case analysis. A probabilistic sensitivity analysis
is conducted to explore the robustness of cost-utility re-
sults to values of input parameters. Results of the prob-
abilistic sensitivity analysis are presented on the cost-
effectiveness plane and in a cost-effectiveness acceptabil-
ity curve.
A 5% significance level will be adopted for all tests and
all tests will be 2-sided. All analyses will be performed
using SAS software, version 9.3 of the SAS System for
Windows.
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Women are recruited by the obstetrician or midwife be-
tween 6–14 weeks of pregnancy during the first routine
antenatal visit. To assess bias in recruitment, eligible
women who decline participation, are asked to give a
limited informed consent to collect data from the elec-
tronic medical files and to fill in a short general ques-
tionnaire on socio-economic factors. Signed informed
consent for participating in the study is obtained before
the first visit of the study. Informed consent includes
permission for gathering data from the medical records,
storage of blood samples for max. 10 years for additional
analyses related to the current study and for the centers
participating in the sub-studies permission for the meas-
urement of the skin fold thickness of the baby at birth
and collection of cord blood.
Figure 2 gives a detailed overview the different study
assessments at the different visits. Study procedures at
each visit (visit 1, visit 2 and visit 3) include blood collec-
tions, anthropometric measurements and self-administered
questionnaires.
Blood collections
Venous blood is drawn by a phlebotomist, nurse or mid-
wife at each study visit. A fasting blood sample is drawn
after a minimum of 10 hours fasting.
 For the GCT, no specific preparation is necessary.
First a blood sample is collected (to later evaluate
the non-fasting glycaemia), followed by a consumption
of a 50 g glucose beverage (Glucomedics®) in 5 minutes
and followed by a second blood sample 1 h after the
intake of the glucose beverage. Data on the time of the
GCT and the time of the last meal are collected.
 For the 75 g OGTT, participants are instructed to be
at least 10 hours fasting and not to smoke nor engage
in any physical activity during the test. They are also
instructed to only drink water, but no coffee, cola or
any drink containing sugar or caffeine. First, a fasting
blood sample is taken, followed by a consumption of a
75 g glucose beverage (Glucomedics®) in 5 minutes.
This is then followed with different blood collections
at 30 minutes, 60 minutes and 120 minutes. At visit 3
women are allowed to continue breastfeeding during
the OGTTand this will be recorded. The participants
complete all the other study assessments during the
2-hour waiting time.
Blood samples for the analyses specifically related to
the study, are in each study site processed, aliquoted and
placed in a-20°C freezer within 90 min of collection.
Every three months blood samples collected at the
study sites are transported by a research assistant from
UZ Leuven to the central laboratory of ExperimentalEndocrinology of the University of Leuven (KU Leuven)
for longer term storage in a −80°C freezer.
Clinical examinations
Blood pressure (BP) is measured twice with 5 minutes
interval using an automatic blood pressure monitor
(Omron Philips large 34-44 cm). Height is measured to
the nearest 0.5 cm using a calibrated wall-mounted sta-
diometer. Weight is measured using a calibrated port-
able Tanita HD 382 digital scale, which measures up to
150 Kg. Waist circumference is measured in centimeters
by applying the tape directly on the skin, horizontally at
the level laterally that is midway between the iliac crest
and the lowest lateral portion of the rib cage.
At visit 1: BP, height, weight and waist circumference
are measured. At visit 2b: BP and weight are measured.
At visit 3: BP, weight and waist circumference are
measured. BMI is calculated as weight (Kg) divided by
height (m) squared.
Self-administered questionnaires
Table 3 gives an overview of the different questionnaires
at each visit.
 Questionnaire on general habits and socio-
economic factors
We use a self-designed questionnaire to extensively
collect information on family history of diabetes,
smoking, alcohol and illicit drug habits, ethnic origin
and education level of the participant and her parents.
We also ask about marital status, employment and
income.
 Questionnaire on lifestyle
We use a questionnaire on lifestyle that has been
previously used to question daily walking activities
and servings per weeks of different important food
categories and beverages [32].
 The international questionnaire on physical
activity (IPAQ)
The IPAQ questionnaire is a wildly used questionnaire
that is also validated for use in the Belgian population
and has also been used in pregnancy [33]. IPAQ
extensively questions different areas of physical activity
such as job-related physical activity, transportation,
house work and caring for family, recreation and time
spent sitting. We have added a question on the time
watching television or playing computer games to
better assess sedentary behavior.
 Questionnaires evaluating tolerance of GCT
and OGTT
We use a self-designed questionnaire to collect
information on the tolerance of the different screening
tests for GDM and also ask for the preference of the
participants for either test.
Figure 2 Overview of the different assessments in the BEDIP-N study.
Benhalima et al. BMC Pregnancy and Childbirth 2014, 14:226 Page 8 of 13
http://www.biomedcentral.com/1471-2393/14/226 Questionnaire on depression
The 20-item Center for Epidemiologic Studies-
Depression (CES-D) has been widely used with
pregnant women and postpartum women to asses
depression symptoms over the past 7 days [34].
 Questionnaire on breastfeeding and contraception
We use a self-designed questionnaire to extensively
collect information on the duration and frequency of
breastfeeding as well as on the type of contraception
used.
 Questionnaire on General health (SF-36)
The SF-36 health survey is used as a questionnaire on
general health and has been validated for use in thematernity context [35]. Data from this questionnaire
are used to calculate Qualy’s to explore the cost
effectiveness of the one-step IADPSG screening
strategy. The SF-36 will be obtained at visit 3 from
women with previous GDM and will be send by mail
to the other participants three months postpartum.Outcomes of the study
The diagnosis of GDM
Diabetes and GDM in early pregnancy are resp. defined
as diabetes and prediabetes outside pregnancy [23]. The
diagnosis of GDM between 24–28 weeks of pregnancy is
based on the IADPSG criteria [9]. For women with a
Table 3 Overview of the different self-administered
questionnaires at the different visits
Visit 1 Visit 2a Visit 2b Visit 3
Questionnaire on general habits and
socio-economic factors
X
Questionnaire on lifestyle X X X
Questionnaire IPAQ X X
Questionnaire on tolerance of GCT X
Questionnaire on tolerance of OGTT X




Questionnaire on general health X
IPAQ: International physical activity questionnaire; GCT: glucose challenge test;
OGTT: oral glucose tolerance test.
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and glycemic control will be collected at each visit with
the diabetes nurse, dietician and/or diabetologist. The
following data are collected: whether glycaemic targets
are met or not, when and why insulin is started and
changes in the dose of insulin. All concomitant medica-
tion and/or supplements will also be recorded.
Pregnancy and delivery outcome data
 Maternal data that are prospectively collected
are: pregnancy duration, preeclampsia (de novo
BP ≥140/90 mmHg > 20 weeks with proteinuria
or signs of end-organ dysfunction), eclampsia,
HELLP syndrome (according to the Tenessee criteria)
[36], gestational hypertension (de novo BP ≥140/
90 mmHg > 20 weeks), preexisting hypertension,
pregnancy-induced cholestasis, ultrasound data
on the presence of hydramnios (amniotic fluid
index >25 cm), abdominal circumference ≥ P95 and
estimated fetal weight ≥ P90 or ≤ P10.
 Delivery data that are prospectively collected are:
type of labor (spontaneous, induced or caesarean
before labor) and the indications if appropriate, type
of delivery (spontaneous vaginal, forceps or vacuum,
caesarean section during labor or planned caesarean
section) and the indications if appropriate.
 Neonatal data that are prospectively collected are:
macrosomia (>4 Kg), LGA (birth weight >90
percentile according to standardized Flemish birth
charts adjusted for sex of the baby and parity), small
for gestational age (birth weight <10 percentile
according to standardized Flemish birth charts
adjusted for sex of the baby and parity), preterm
delivery (<37 completed weeks), 1 and 5 min Apgar
score, shoulder dystocia, birth trauma, neonatal
respiratory distress syndrome, congenital anomalies,neonatal hypoglycaemia, neonatal jaundice,
hypocalcaemia, hypomagnesemia, polycythaemia
and duration and indication for admission on the
neonatal intensive care unit. Neonatal blood analyses
are only done if there is a clinical warning sign in
accordance with local practice.
Researchers are asked to evaluate whether the main
reason of the maternal and neonatal complications and
management is related to diabetes or GDM.
Other study measurements
Evaluation of insulin sensitivity and beta-cell function during
pregnancy and postpartum based on the OGTT
At the three visits blood samples are taken to later de-
termine HbA1c and insulin (fasting and at the different
time frames of the 75 g OGTT). These analyses will be
performed in all women with diabetes or GDM and in a
control group of women without diabetes or GDM. Ana-
lyses will be performed at the central lab of UZ Leuven.
HbA1c is measured by reversed-phase cation-exchange
chromatography (ADAMS HA-8160, Menarini Diag-
nostics Benelux, Zaventem, Belgium). Plasma glucose is
measured by an automated colorimetric-enzymatic method
(hexokinase-glucose-6-phosphate-dehydrogenase, applica-
tion 668) on a Hitachi/Roche-Modular P analyzer. Insulin
is measured by the immunometric ECLIA (Roche Modular
E170, Basel, Switserland).
Glycaemia will be assessed by the area under the glu-
cose curve during the OGTT, calculated using the trap-
ezoidal rule. Insulin sensitivity will be measured using
the insulin sensitivity index of Matsuda and DeFronzo
[37]. Beta-cell function will be assessed by the insulino-
genic index dived by HOMA-IR [38]. The insulinogenic
index will be calculated as the incremental change in in-
sulin concentration during the first 30 min of the OGTT
divided by the incremental change in glucose during the
same period [39,40]. As a measure of beta-cell compen-
sation, the insulin secretion sensitivity index (ISSI-2) will
be measured [41,42]. All these measures are validated
for use in pregnancy.
Measurement of lipids and inflammatory biomarkers
Based on blood samples taken at visit 1, lipids (total
cholesterol, HDL, triglycerides, calculated LDL), 25-OH
vitamin D and the inflammatory biomarkers adiponectin,
leptin and Hs-CRP will be measured at the Lab of
Experimental Endocrinology of KU Leuven in the group
with diabetes/GDM and in a subgroup of women without
diabetes or GDM. Lipids will also be measured at visit 2
and visit 3. Lipids are measured by the immunoassay
analyzer Cobas 8000 (Roche). Hs-CRP, leptin and adipo-
nectin will be measured by the immunoassay system of
Meso Scale Discovery, Gaithersburg, USA (coefficients of
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for adiponectin). 25 OH vitamin D will be measured by
the competitive radioimmunoassay (DiaSorin, Stillwater,
Minnesota, USA) as previously described [43].
Measurement of the thyroid function
Since (subclinical) hypothyroidism is related to an in-
creased risk for GDM, the thyroid function will be mea-
sured at visit 1 with TSH and total T4 and at visit 3 with
TSH and free T4 [44]. Total T4 will be measured at the
central lab of UZ Leuven. In UZ Leuven TSH is mea-
sured by immunometric ECLIA (Roche Modular E170,
Basel, Switserland) and total T4 and free T4 by competi-
tive ECLIA (Roche Modular E170, Basel, Switserland).
Measurement of antibodies according to the routine
guidelines of the Belgian Diabetes Registry (BDR)
In women with diabetes or GDM, extra blood samples
will be taken during their routine follow up by the dia-
betes team for the measurement of antibodies by the lab
of UZ Brussels in accordance with the normal BDR
regulations: new diagnosis of diabetes or GDM in
women < 40 years. The antibodies that will be measured
are: insulin antibodies (IAA), protein tyrosine phosphatase
antibody IA-2A and glutamic acid decarboxylase (GAD)
antibody as described previously by the BDR [45].
Screening for MODY-2
In women with a FPG ≥92 mg/dl (5.1 mmol/l) at visit 1
or visit 2B, analysis of the genetic mutation predisposing
to MODY-2 will be performed at the medical genetics lab
at UZA (MODY MASTR assay of Multiplicom with se-
quencing on MiSeq Illumina) in the following subgroups:
 In women at visit 1 or visit 2B with FPG ≥92 mg/dl
(5.1 mmol/l) and a history of a first degree relative with
diabetes/GDM or a prepregnancy BMI <25 Kg/m2.
 In a subgroup of women with FPG ≥92 mg/dl
(5.1 mmol/l) in early or late pregnancy without
family history of diabetes or with a BMI ≥25 Kg/m2.
Evaluation of the newborn within 3 days after delivery
 Data from the routine clinical examination are
collected: weight, length and head circumference
 In 4 participating centers (UZ Leuven, UZA, OLV-
Aalst-site Asse and Imelda Bonheiden): measurement
of the triceps, subscapular and flank skinfold
thickness (two consecutive measurements are taken
and recorded, the mean will be calculated) with a
Harpender skinfold caliper for the calculation of the
percentage of body fat as previously described in
the HAPO study [46]. The measurements will be
performed by a trained physician, nurse or midwife.Participating health care workers receive training for
the skinfold measurements at UZ Leuven.
 In 5 participating centers (UZ Leuven, UZA, OLV-
Aalst-site Asse, Imelda Bonheiden and St Jan hospital
Brussels): cord blood will be collected both in women
with and without diabetes/GDM for storage in the lab
of Experimental lab of Endocrinology of KU Leuven
for later analyses of C-peptide, lipids and leptin [2]. An
extra sample of cord blood will also be collected for
later epigenetic research. Since it is not yet defined
which specific epigenetic research will be performed, a
new application to the ethical committees will be done
for this research.
A standardized protocol in line with routine care for the
treatment of diabetes/GDM
Within 2 weeks after the diagnosis, women will receive
advice from the dietician and the diabetes nurse. A follow
up visit and/or telephonic or email contact is planned every
7–14 days until the delivery with the dietician and/or dia-
betes nurse under the supervision of the diabetologist. If
insulin is needed, a follow up visit and/or telephonic or
email contact is planned every 7–14 days with the diabetol-
ogist until the delivery.
Dietary advice
Women will receive personal advice by a dietician. The
institute of Medicine (IOM) guidelines for weight gain
are followed [47].
Physical activity
If there are no contra-indications according to the ob-
stetrician for the safety of the pregnancy, regular moder-
ated physical activity, defined as 30 min physical activity
five times a week, is advised.
Self-monitoring of blood glucose
The self-monitoring of the blood glucose will have to be
performed at least 4 times daily (fasting and postprandial
after three meals) during the first two weeks after diagno-
sis and thereafter at least four measurements per day
during at least two days per week. The mean glycemic
targets are a FPG < 95 mg/dl (5.3 mmmol/l) and 1-h after
the meal <140 mg/dl (7.8 mmol/l) or 2 h after the
meal <120 mg/dl (6.6 mmol/l). Centers are at liberty to
choose whether the postprandial glucose level is measured
after 1 h or 2 h, in accordance with their current practices
but the blood glucose should always be measured at the
same time interval in any given subject. For the study, only
one type of glucometer (BGStar, Sanofi) is used in all cen-
ters as this will allow for more uniformity.
To uniform the initiation for insulin therapy, the
‘Weekly Average Glycaemia’ (WAG) will be calculated
based on the self-monitoring values of the blood glucose
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Therapy with Insulin will become necessary if the fol-
lowing targets are not reached:
 Fasting WAG ≥95 mg/dl (5.3 mmol/l) two weeks in
a row (start of basal insulin)
 Postprandial WAG ≥140 mg/dl (7.8 mmol/l) (1 h)
or ≥120 (6.6 mmol/l) (2 h) two weeks in a row (start
of prandial insulin)
 Fasting and postprandial WAG over the target two
weeks in a row (start of basal and prandial insulin)
 Due to obstetrical conditions such as
polyhydramnios and macrosomia, according to the
judgment of the obstetrician
 Fasting and postprandial WAG in the target with
one or several particularly high glycaemia levels
Treatment with oral antidiabetics including metformin
and glibenclamide are not allowed in the study.
Permitted insulins during the study are:
 The short and long acting human insulins.
 The short acting insulin analogues Lispro and Aspart.
 Glargine will not be used during the study since
there is no official approval for use during
pregnancy. Detemir can be used during pregnancy
but this is only reimbursed for T1DM in Belgium.
Quality control procedures
Every site is opened after a first initiation visit. During
the study conduct, the coordinators of the study will
conduct periodic monitoring visits of sites to ensure that
the protocol is being followed. A monitoring visit for all
sites will be performed at least once during the enroll-
ment process. A research assistant of UZ Leuven will
visit each study site at least every three months to collect
the blood samples for transportation to the central lab
of UZ Leuven and will also perform regular monitoring.
Detailed manuals were developed describing the data
collection at the different visits and the handling of
the blood samples. Any unanticipated (serious) adverse
events (AE/SAE) occurring within start of the study is re-
corded by the investigator on the specific AE/SAE pages of
the CRF in terms of nature of the event, date, outcome,
and action taken. If the AE meets the definition of an SAE
(according to the judgment of the investigator), the investi-
gator must complete the SAE Report Form in addition.
Research staff completes training led by the Principal
investigator. Training for the skinfold measurements is
organized during half a day at UZ Leuven.
A database in “Filemaker Pro” has been developed spe-
cifically for this study to enter all the study data. This
includes all data from the different visits, prenatal anddelivery outcome data and blood analyses. Data from the
questionnaires are processed by “teleform” and then
exported to the database. Each participant gets a subject
identification number to ensure confidentiality of the data.
All data collected in this study are referred to by subject
identification number only. All data are stored in a secure
manner through password protection.
Different strategies are in place to increase participation
and retention. Posters, flyers and a website have been devel-
oped to give information to as many pregnant women as
possible. To increase recruitment of women with an ethnic
minority background, flyers are available in Dutch, French
and English and the informed consent is available in Dutch,
French, English, Arabic and Turkish. The study provides
the participants, the primary care physician and the obstet-
rician with the results of the FPG at the first visit and with
the results of the OGTT’s at the later visits. Women are
allowed to breastfeed during the OGTT postpartum. Incen-
tives for the participants include remuneration of the trans-
portation costs by a 5 euro gift card for attending visit 1
and a 10 euro gift card for attending visit 2a. Retention is
maximized by phone or email contact before each sched-
uled study visit. In addition, contact information is con-
firmed at any in-person, phone or email contact.
Discussion
BEDIP-N is the first study involving a large European
cohort that rigorously assesses diabetes and GDM in
early pregnancy and universally screens for GDM later
in pregnancy using both a GCT and 75 g OGTT with
the IADPSG criteria. Strengths of the study are the large
cohort that is recruited from both university and non-
university centers with a good mix of centers with an
average number of women with a BME background and
centers with a high percentage of women with a BME
background. This increases our chances to obtain a rep-
resentative sample which will permit generalizability of
the findings to the whole Belgian population.
A particular advantage of BEDIP-N is the detailed
registration of many clinical and biochemical risk factors
for diabetes and GDM with the first collection of data in
the first trimester. Moreover very detailed data on diet-
ary habits, physical activity and socio-economic status
are collected. This is to our knowledge also the first
study to evaluate the value of the IADPSG criteria in a
two-step procedure with a 50 g GCT with the aim to
explore the cost effectiveness of the one-step IADPSG
screening strategy compared to other screening ap-
proaches (risk factor and two-step).
The BEDIP-N study also has strong potential to better
elucidate the underlying pathophysiological mechanisms
of GDM. The study includes an extensive evaluation
of the insulin sensitivity and beta-cell function during
pregnancy and postpartum based on the OGTT. The
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evaluated in this cohort. BEDIP-N also plans extensive
evaluation of newborns with the measurement of skinfold
thickness to better evaluate the percentage of body fat
and with the collection of cord blood for the evaluation
of fetal hyperinsulinaemia.
Since this is an observational study, women are not
randomized to a two-step versus a one-step screening
strategy and all women are diagnosed and treated based
on the 75 g OGTT. Another limitation is that the study
is not powered to evaluate rarer complications such as
shoulder dystocia and birth trauma. The follow up of the
study is limited to three months postpartum for women
with a previous history of GDM and the study will there-
fore not inform on the risk to develop diabetes and pre-
diabetes in the long term.
Findings of the BEDIP-N study may have a significant
public health impact since data from the study may
translate into the development of a cost effective and
simple screening algorithm for GDM. A better un-
derstanding of the underling mechanisms of the de-
velopment of GDM might also guide further follow up
and treatment.
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